A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000012208
- Lead Sponsor
- Kurume University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of hypersensitivity reaction 2) Brain metastasis 3) Pleural effusion, ascites, and pericardial fluid requiring treatment 4) Active another cancer 5) Active infection 6) Other severe complications, such as heart failure, interstitial pneumonia and renal failure with clinically problem 7) Required treatment with steroid 8) Pregnant or possibility pregnancy or nursing women 9) Mental disorder which become problem on clinical practice 10) Physician judged improper to entry this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Progression-free survival Overall survival Safety